Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCTPP1 | Q9H773 | 2/20 | 0.50 |
| ▸ | PPARG | P37231 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 7/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.44 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.44 |
| ▸ | PITRM1 | Q5JRX3 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6309555 | 0.88 | PPARG (0.49) | DCTPP1PPARGMEN1KMT2APOLB | |
| SCHEMBL7651458 | 0.88 | PPARG (0.56) | DCTPP1PPARGAGTR1AGTR2 | |
| SCHEMBL6170044 | 0.85 | PPARG (0.64) | DCTPP1PPARGMEN1KMT2ARAB9A | |
| SCHEMBL7656331 | 0.83 | PPARG (0.52) | DCTPP1PPARGAGTR1AGTR2 | |
| SCHEMBL6309778 | 0.83 | PPARG (0.52) | DCTPP1PPARGAGTR1AGTR2 | |
| SCHEMBL6309647 | 0.82 | PPARG (0.54) | DCTPP1PPARGAGTR1AGTR2 | |
| SCHEMBL6298966 | 0.82 | KMT2A (0.51) | DCTPP1MEN1KMT2APOLBGAA | |
| SCHEMBL6169166 | 0.82 | PPARG (0.57) | PPARGRAB9A | |
| SCHEMBL6303642 | 0.81 | PPARG (0.51) | DCTPP1PPARGAGTR1AGTR2 | |
| SCHEMBL6307363 | 0.81 | PPARG (0.51) | PPARGAGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6420409-B1 | GLUCOSE TOLERANCE, DIABETES,INSULIN RESISTANCE, POLYCYSTIC OVARY SYNDROME, HYPERLIPIDEMIA, ATHEROSCLEROSIS, CARDIOVASCULAR DISORDERS, HYPERGLYCEMIA, HYPERTENSION, STENOCARDIA, PULMONARY HYPERTENSION, CONGESTIVE HEART FAILURE, | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-07-16 | — | — | US | disclosed |
| EP-1020452-A1 | BENZIMIDAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-19 | — | — | EP | disclosed |